611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO, CA
Topline ACCESS II and Supplementary Studies
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Material Agreement with Genentech for GLP-1 Receptor Agonists
Structure Therapeutics Announces Follow-On Public Offering of ADSs
Topline ACCESS Phase 2b Results
Reports Third Quarter 2025 Financial Results and Recent Highlights
Financial Results, Press Release
Shareholder votes
FY 2025
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership